Manhattan Scientifics, Inc.
MHTX · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.03 | 0.00 | -0.10 |
| FCF Yield | -2.53% | -2.42% | -0.96% | -1.47% |
| EV / EBITDA | -4.33 | -9.09 | -5.70 | -13.82 |
| Quality | ||||
| ROIC | 7.01% | 9.04% | 8.67% | 12.10% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.11 | 0.11 | 0.06 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -71.99% | -72.86% | -72.86% | – |
| Free Cash Flow Growth | 59.52% | -200.00% | 62.16% | 42.19% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | -0.05 | 0.03 | 0.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -11,970.00 | 0.00 |